Index

A

abbreviated new drug applications (ANDAs) 246–260
abridged regulatory pathways 114
ACCESS Consortium 117–121, 189
active implantable medical devices (AIMDs) 355
  ARTG requirements for 38
  biological safety 357
  country-specific requirements 361–364
definition 356–365
electrical/electromagnetic safety 358
general standards 357–365
heat 359
markings and symbol requirements 359
mechanical safety 359
MRI imaging/medical treatments risks 358
radiofrequency communication 359
regulatory approval principles 360–361
sterilization and packaging 358
surgical technique validation 359
active pharmaceutical ingredient (API) 207, 230
  Active Substance Master File (ASMF) 397
adult stem cells 543
advanced therapy medicinal products (ATMPs) 397.
  See cell-based medicinal products testing and control parameters for 397
adverse drug reaction (ADR)
  ICH E6(R2) definition 27
  occurrence and categorization 282
  OTC postmarket reporting 264–271
adverse event (AE)
  ICH E6(R2) definition 27
  MDIR System report 39
  national level reporting (devices) 381–388
  regional reporting requirements 283, 285
  reporting requirements 282–285
advertising and promotion
  advertising definitions and types 57
  direct-to-consumer regulation 60
  ethical criteria 59
  for devices 386
  free sample use in 61
government regulation 58
healthcare product regulation 57–58
international 55, 59
over-the-counter (OTC) products 60, 263–271
pharmaceutical harmonization 60
promotion definitions and types 57
sales professionals in 61
self-regulation 58
Africa. See also Middle East and North Africa (MENA) countries
  biosimilar product regulation 453
  cosmetic product regulation 636
Africa and Middle East
  universal health coverage (UHC) 156
Africa and Middle East (AME) region. See also Middle East and North Africa (MENA) countries
  biotechnology product regulation 408–409
  HTA implementation 156
  orphan products 519
  pharmaceutical product regulatory harmonization 189–202
  regulatory organizations in 6–7
African Medicines Agency (AMA) 189
African Medicines Regulatory Harmonization (AMRH) 6
ALCOA+ 73
Algeria, pharmaceutical product regulation 189–202
Americas. See The Americas
animal rule
  for device conformity 317
  US biotechnology products 399
ANVISA. See Brazil
APEC Life Sciences Innovation Forum (APEC LSIF)
  IMDRF regional harmonization 4
  Regulatory Harmonization Steering Committee (RHSC) 5
Argentina
  biosimilar product regulation 453
  climactic zone and stability testing 217–219
  device traceability and tracking 106
generic drug product market 250–260
  orphan drug regulation 517

Regulatory Affairs Professionals Society 713
Index

pharmaceutical product regulation 201
traceability and code for medicines 106–111
Asia
biotechnology products 403–409
format for MAA 178
HTA adoption in 159–176
HTA status of selected countries 157
in-country representation requirements 36, 51
pharmaceutical product regulation 194–202
Asian Harmonization Working Party (AHWP) harmonization efforts 5
IMDRF harmonization initiatives 4
Asian-Pacific Economic Cooperation (APEC) 5
Asia-Pacific (APAC) region
 cosmetic product regulation 635
 key generic drug product markets 254–260
 orphan drugs 517
 Asia Pacific region
country-specific climatic zones 216
Association of British Healthcare Industries (ABHI) 58
Association of Southeast Asian Nations (ASEAN)
adverse event reporting requirements 285
CTD/ACTD format use in 178
generic drug product requirements 255–260
harmonization of cosmetic regulation 635
membership of 5
MRA for pharmaceutical products 238
pharmaceutical product regulation 194
postmarketing pharmaceutical product requirements 278
stability testing requirements 215–219
stability testing requirements 215–219
Association of Southeast Asian Nations Pharmaceutical Product Working Group (ASEAN PPWG) 5
Association of the British Pharmaceutical Industry (ABPI), advertising and promotion regulation 58
audit trail, ICH E6(R2) definition 27
Australia
AIMD requirements 361–365
biosimilar product regulation 445, 450
cosmetic product regulation 636
COVID-19 vaccines provisional registration 470
CTD format for MAA submission 178
essential principles for IVDs 350–354
generic drug product regulation 256–260
HTA process for reimbursement 164
HTA use in 163–176
human blood and plasma products 498
in-country representation laws, regulation, guidelines list 35
in-country representative functions 37
IVD classification 350
IVD clinical trial requirements 350
IVD conformity assessment 352–354
IVD regulations 349–354
orphan market exclusivity 512
orphan product regulation 518
OTC products and switching procedures 267–271
pediatric drug/research development 618
pharmaceutical product regulation 198–202
postmarketing pharmaceutical product requirements 278
Project ORBIS 119
regulation and inspection process alignment 231
Rule 9 special classification 352
vaccine regulation 464
Australian Influenza Vaccine Committee (AIVC) 468
Australian Public Assessment Reports for prescription medicines (AusPARs) 38
Australian Register of Therapeutic Goods (ARTG) listing
 application 38
 changing product sponsor 39
 in-country representation 37
 Austria, inspection process 231
authorised representative. See in-country representation authorised representative, qualifications in EU 43
authorization procedures (pharmaceutical products) 187
country-specific marketing authorization procedures 189–206
regulatory convergence and cooperation 188–206
Ayurveda. See traditional medicine (India)

B
batch release
 stability testing of drug product 210
biocompatibility
device materials 316
Biological Medicines Evaluation and Research Unit (BERU) 453
biological safety, AIMDs 357
Biologics and Genetic Therapies Directorate (BGTD), vaccine regulation 463
biosimilar products 411, 413, 415
approved products 438, 447
Asia 439
basic and recent developments 412
current procedures and guidance 424
equivalence/noninferiority designs 417
ICH regions 418
marketing approval by centralised procedure 419
regulatory definitions, nomenclature, and terminologies 413
regulatory terminology guidelines 413

714 Regulatory Affairs Professionals Society
| SBP licensing principles (WHO) | 416 |
| stakeholder influence | 415 |
| standalone vs. abbreviated development | 432 |
| biosimilar products (EU) | adopted by CHMP | 424 |
| guidelines for | 425 |
| history and legal framework | 418 |
| biosimilar products (India) | approved/marketed | 443 |
| history/overview | 439 |
| biosimilar products (Japan) | approved products | 438 |
| current procedures and guidance | 437 |
| history/overview | 434 |
| biosimilar products (US) | current procedures and guidance | 433 |
| FDA meetings for applications | 431 |
| general requirements | 433 |
| history and legal framework | 426 |
| interchangeability requirement | 434 |
| biotechnology products | see also vaccines |
| Active Substance Master File | 397 |
| advanced therapy medicinal products | 397 |
| definition and scope | 392 |
| EU and US evaluation | 392–409 |
| PAHO | 405–409 |
| quality and manufacturing information | 395–409 |
| transmissible spongiform encephalopathy | 396 |
| viral clearance/extraneous agents | 396 |
| biotechnology products (Asia) | clinical trials | 404 |
| current procedure and guidance | 403–409 |
| history/overview | 403–409 |
| ICH and ASEAN CTD structure | 404 |
| biotechnology products (Canada) | clinical trials | 403 |
| current procedures and guidance | 402 |
| dossier requirements | 403 |
| lot release | 403 |
| overview and history | 402 |
| biotechnology products (EU) | dossier requirements | 394 |
| recombinant DNA technology | 394 |
| registration procedures | 393–409 |
| release testing in Europe | 397 |
| biotechnology products (Japan) | current procedures and guidance | 401 |
| dossier requirements | 402 |
| overview/history | 401–409 |
| biotechnology products (LATAM) | clinical trials | 407 |
| current procedure and guidance | 407–409 |
| dossier requirements | 407–409 |
| history/overview | 406–409 |
| biotechnology products (US) | confidentiality arrangements | 398 |
| current procedures and guidance | 398 |
| dossier requirements | 399–409 |
| import/export | 401 |
| inspections | 400 |
| lot release | 400 |
| manufacturing arrangements | 400 |
| overview/history | 398 |
| biotherapeutic products. See biosimilar products |
| blinding/masking |
| ICH E6(R2) definition | 27 |
| Blood Action Plan | 494 |
| botanical drug products (BDPs) | 575 |
| clinical studies | 591 |
| CMC information for | 588–593 |
| conventional drug comparison | 589 |
| definition and exclusions | 584 |
| direct-to-OTC criteria | 585 |
| IND development process | 586–593 |
| information for IND | 587 |
| marketing regulatory pathway | 582 |
| OTC approval route | 586 |
| practical development issues | 591 |
| preclinical studies for NDA | 590 |
| quality, safety and efficacy standards | 584 |
| regulations in selected countries | 579 |
| routes for market entry (US) | 585–593 |
| strategic development considerations | 588 |
| bovine spongiform encephalopathy (BSE) | 396 |
| Brazil | 69 |
| AIMD requirements | 363 |
| biosimilar dossier requirements | 452 |
| biosimilar product regulation | 451 |
| device INMETRO certification | 74 |
| generic drug product market | 249–260, 257 |
| GMP certificate for marketing | 75 |
| harmonization of inspection process | 231 |
| human blood and plasma products | 501 |
| ICH Q7 adoption | 69 |
| in-country representative requirements | 39–40 |
| ISO 13485 use | 328–331 |
| laws, regulations, and guidelines list for in-country representation | 35 |
| liability of in-country representative | 40 |
| medicinal product serialization | 107–111 |
| orphan drug evaluation | 517 |
| postmarketing pharmaceutical product requirements | 278 |
| postmarket surveillance/vigilance | 40 |
| Project ORBIS | 119 |
| stability testing and climactic zone | 217–219 |
| Brazilian Health Surveillance Agency (ANVISA) |
| biosimilar product regulation | 451 |
Index

human blood and plasma products 501
orphan drug evaluation 517
pharmaceutical product regulation 201–202
Brazil Registration Holder (BRH) 40
Brazil, Russia, India, and China (BRICS) generic drug product markets 257
Brexit regulatory effects. See United Kingdom (UK) budget-impact analysis (BIA) 145

C

Canada advertising and promotion regulation 58
AIMD requirements 363
biotechnology products regulation 402–409
combination products 532–539
cosmetic product regulation 633
CTD format for MAA 178
generic drug products regulation 248
HTA implementation in 166
human blood and plasma product regulation 497
in-country representation laws, regulations and guidelines summary 35
influenza vaccines 468
ISO 13485 compliance 328
IVD regulations 352–354
mandatory problem reporting for devices 386
OTC products regulation and switch procedures 266–271
pediatric research promotion 616
postmarketing pharmaceutical product requirements 279
Project ORBIS 119
public system reimbursement decision pathway 169
regulation and inspection process in 231
vaccine regulation 463
Canadian Agency for Drugs and Health Technologies (CADTH) drug review process 161
elements and recommendations categories 166
HTA implementation 166
Canadian IVD regulations classification 352–354
clinical trial requirements 352
Medical Device License (MDL) 353
Caribbean Community and Common Market (CARICOM) 119
Caribbean Community and Common Market (CARICOM), pharmaceutical products regulation 200
Caribbean Public Health Agency (CARPHA) 119
Caribbean Regulatory System (CRS) activities of 119
legal authority of 119–121
pharmaceutical products regulation 200
case report form (CRF), ICH E6(R2) definition 27
cell-based medicinal products 541, 543
applicable guidelines 559
approved ATMPs (US, EU, Japan) 545
ATMP approval centers (US, EU, Japan) 550
COVID-19 breakthroughs 544
COVID-19 risk with ATMP 548
COVID-19 transmission risk in manufacturing process 548
COVID-19 treatments 547
dosage of medicinal products 546
good manufacturing and distribution practices 69
industry/regulatory challenges 559
overview of types 542–560
process development framework 547, 546–560
regulatory framework 550
regulatory guidelines (US, EU, Japan) 549
research areas and commercial approvals 544
cell-based medicinal products (EU) regulatory guidelines 555
regulatory pathway 550
regulatory processes 551
cell-based medicinal products (Japan) regulatory guidelines 557
regulatory pathway 558–560
cell-based medicinal products (US) regulatory guidelines 554
regulatory pathway 553
regulatory scenarios 553
cell therapy medicinal products (CTMPs) 543
CE marking/certificates of compliance for compliance 330
Center for Biologics Evaluation and Research (CBER), blood/blood product regulation 493
Center for Food and Drug Inspection (CFDI), manufacturing site inspections 231
Central Drugs Standard Control Organization (CDSCO) biosimilar guidelines 439
orphan product application 519
Central Drug Standards Control Organization (CDSCO) GMP inspections for pharmaceutical 232
pharmaceutical product regulation 196
centralised procedure biosimilar marketing approval 419
criteria for use 394
history 393
marketing authorization through 393
product registration in EU 394
Central Social Insurance Medical Council (Chuikyo) 163
Centre for Blood and Tissues Evaluation (CBTE) 497
CEP certification inspections for 230 revocation 229
Index

pharmaceutical products 277
comparator (product), E6(R2) definition 28
competency (regulatory reliance) 117
complementary and alternative medicine (CAM) 581
herbal product definitions 581
licensing/credentialing of professionals 581
complementary health approaches (CHA) 581
complementary medicine (CM) 576
compliance and enforcement (pharmaceutical products) 19, 65
advertising and promotion 73–81
anti-corruption 74–81
crisis management 13
electrical, environmental, and wireless device requirements 74–81
EU pharmaceutical products 229
GCP principles 26
GMP requirements for 69
import alerts/distribution bans 78
market authorization requirements 74–81
postmarketing pharmaceutical products 273
recalls/market withdrawal/stock recovery 78
role of professional in 79–81
scope of regulations 66–81
surveillance 76–81
trade 74–81
Compliance Program Guidance Manuals (CPGM) 223–224
compulsory licenses (CLs)
generic drug products 257
conditional marketing authorisation (CMA) 470
Confederation of Independent States (CIS) biotechnology product regulation 408
conformity assessment
IVD devices 335
QMS requirements for devices 323
stages of 351
conformity assessment elements
Class A Device 294
Class B Device 295
Class C Device 296
Class D Device 297
device classification relationship 338
IVD devices 335–354
quality management system 321
consistency 117
contract, E6(R2) definition 28
contract research organization (CRO)
ICH E6(R2) definition 27
Convention on the Elaboration of a European Pharmacopoeia 182
corrective action preventive action (CAPA) system pharmaceutical quality 275
corrective and/or preventive action (CAPA) IVD premarket requirement 337
Corrective and preventive action (CAPA) for software 376
cosmetic products
Australian regulations 636
Canadian regulatory process 633
European regulatory process 630
history 629
Japanese regulation 636
Latin American countries regulation 634
Middle East and African regulation 636
regulation of 629
regulatory overview 630
regulatory requirements 3
South Korean regulation 636
US regulatory process 631
Cost and Economic Evaluation (ECO) 147
cost-based pricing (CbP) model 127
cost-benefit analysis (CBA) 145
cost-effectiveness analysis (CEA) 145
cost-minimization analysis 145
cost-of-illness analysis 145
cost-utility analysis (CUA) 145
Council of Europe 225
counterfeit and regulation
European legal requirements 97–111
exemptions by individual states 101
international 87
legal actions for control of 91
occurrence and prevention of 88–109
reported substandard/falsified products 105
rest of the world 104–111
risk reduction methods/traceability 90
terminology for 89
terminology inconsistencies 88
US legal requirements 91–111
Creutzfeldt-Jakob Disease (vCJD) 396
crisis management
definitions and factors in 11
healthcare product industry 11
off-label use and whistle blowers 15
organizational crises 14
phases of 15–17
postmarketing safety events 13
product crises 12–17
regulatory crises management 13–17
safety and/or efficacy concerns 12
critical deficiency 224
critical process and data identification, E6(R2) 30
current good manufacturing practice (CGMP).
See good manufacturing practice (GMP)
cybersecurity, for device software 376
D
Danish Centre for HTA (DACEHTA) 146
Data and Safety Monitoring Board, E6(R2) definition 28
data monitoring committee, E6(R2) definition 28
debarment 78
Declaration of Conformity
device premarket requirements 295
EU in-country representative 44
for IVDs 338
Table of Contents (ToC) format for RPS 315
Declaration of Helsinki 23
Description and Technical Characteristic of Technology (TEC) 147
design qualification (DQ), GHTF guidance 330
development safety update reports (DSURs),
pharmaceutical label changes 277
device classification
active device decision tree 306, 307
additional rules 308
device class and rules 335
invasive device classification decision tree 304, 305
IVD device classification 333
noninvasive classification decision tree 303
device conformity assessment 293
device Identifier (DI) 96
device package, definition 97
device premarket requirements
active devices 301
additional rules 302
classification rules 297
conformity assessment principles 293
declaration of conformity 295–302
design and manufacturing requirements 291–302
device definition 290–302
harmonized conformity assessment procedures 296
invasive devices 299
manufacturer/device registration 296
medical devices classification principles 297
noninvasive devices 298
Quality Management System (QMS) 293–302
registration with regulatory authorities 296
safety and performance requirements 291–302
standards in medical device assessment 298
summary technical documentation 294–302
device registration, IVD devices 338
diagnostic or measuring function of devices 292
dietary supplements. See food supplements
direct-to-consumer (DTC) advertising and promotion 60
countries allowing 60
de facto advertising 60
prescription drug advertising 73
documentation, MRCT requirements 21
dossier requirements 177
biosimilar application (Brazil) 452
biosimilar applications in Japan 440
biosimilar marketing application (China) 446
biosimilar marketing application (India) 441
biosimilar product applications 448
biosimilar product marketing application in EU 427
biotechnological products (LATAM) 407–409
biotechnology products (Canada) 403
IMPD for vaccines 462
pandemic dossier requirements 468
US biosimilar applications 435
vaccines 471
vaccine submissions 461
veterinary medicinal products 644
Drug Master Files (DMFs)
eCTD format for 179
for generic drug products 247
for vaccines 468
drug product (finished pharmaceutical product),
stability testing 207
drug products. See pharmaceutical products
drug substance 207
E
Economic Community of West African States (ECOWAS) membership 6
efficacy assessment, E6(R2) specifications 28
Efficacy Working Group (M4E) 179
Egypt, pricing of medical services 156
embryonic stem cells 543
emergency use authorizations (EUA) 470
endometrial carcinoma therapy testing 119
energy source connection for devices 292
England. See also United Kingdom (UK)
HTA programs/bodies in 154
process map for 154
environmental standards, IVDs 339–354
essential health service package (EHSP) 158
essential principles, device safety and performance 290
Ethical Analysis (ETH) 147
Ethiopia, EHSP implementation 158
ethnic factors/foreign clinical data (E5(R1) 24
EU Ad hoc Influenza Working Party 467
EU Clinical Trial Information System (CTIS) 395
EUDAMED
device lifecycle information 103
reporting platform 48
EudraGMDP database 229
EU-level Transparency Committee 125
EUnetHTA 147
Eurasia/Eurasian Economic Union, pharmaceutical
product regulation 201
Index

Eurasia, implementation of harmonization in 5
Eurasian Economic Union (EAEU/EEU), harmonization 5
European Biosimilars Working Party (EBWP) 415
European Collaboration on Health Technology Assessment (ECHTA) 146
European Commission (EC) 225
HTA studies 146
ICH Q7 adoption 69
initiatives on pricing and reimbursement 126
medicinal price/reimbursement controls legal framework 125–142
pandemic influenza dossier approach 468
software as medical device 369
Transparency Directive update 125
US-EU Mutual Reliance Initiative audit 120
European Conformity (CE) Mark for software 374
postmarket surveillance system requirements 380
European Directorate for the Quality of Medicines and Healthcare (EDQM) 182, 225
Certificate of Suitability 396
inspection for certification 230–241
medicinal product and vaccine regulation 461
European Falsified Medicines Directive (FMD) aims and scope of 97–109
requirements 98–109
European Federation of Pharmaceutical Industries and Associations (EFPIA) use of free samples in advertising 61
European Federation of Pharmaceutical Industries and Associations (EFPIA), harmonization of advertising and promotion 57
European Food Safety Authority (EFSA) 570
European Medicines Agency (EMA) biosimilar marketing approval pathway 415
clinical trial guidance 20
Committee on Herbal Medicinal Products (HMPC) 583
core pandemic dossier approach 468
eCTD submissions 179
generic pharmaceutical product deviation 244
inspection guidance 225
in-use stability testing of drug product 214
mutual recognition agreement with FDA 120
Pharmacovigilance Risk Assessment Committee (PRAC) 277
post inspection certificates 77–81
product quality defect reporting 79
vaccine adjuvants vs. immunomodulators 466
European Network for Health Technology Assessment (EUnetHTA) Project 146
European Organisation for Rare Diseases (EURORDIS) 509
European Pharmacopoeia (EP ) 236
European Public Assessment Report (EPAR) 394
European Union (EU) advertising and promotion regulation 58
AIMD requirements 361
combination products 533–539
cosmetic product regulation 630
CTD format for MAA submission 178
EU EUDAMED 103–111
EudraGMDP database 229
European Falsified Medicines Directive 97–111
EU Unique Device Identifier (UDI) System 102–111
GCP standards use 19
generic drug market in 251
gene therapy guidelines 469
HTA development in 146
in-country representation for devices 40
in-country representation laws, regulations and guidelines 35
in-country representative changes 49
inspection process 76–81, 225
Instruments 226
investigational medicinal products (IMPs) trials 394
In Vitro Diagnostic Medical Device Regulation 340
ISO 13485 compliance 328–331
medical device software requirements 377
orphan products 517–520
OTC products and prescription switch 264–271
periodic safety update report (PSUR) 285
postapproval pharmaceutical product variation reporting 280
postmarket surveillance system 380
pricing and reimbursement 123, 123–142
pricing and reimbursement models used in 126–142
pricing and reimbursement policies 123–124
regulations and legal framework 225
regulatory authorities 225
software classification 373–378
software regulation 369–378
vaccine adjuvant requirements 466
VICH program 4
EU Unique Device Identifier (UDI) System aims and scope of 102–109
Basic EU UDI-DI definition 102
implementation timeline 103–109
implications and challenges 104–109
labeling requirements 103–109
requirements and implementation 102–109
evidence-based guidance, NICE use of 154
evidence-based international standards 7
Expert Committee on Biological Standardization (ECBS) 415
Expert Committee on Biological Standardization (ECBS) guidance 459
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experts on the Rational Use of Drugs</td>
<td>59</td>
</tr>
<tr>
<td><strong>F</strong></td>
<td></td>
</tr>
<tr>
<td>Falsified Medicines Directive (FMD)</td>
<td></td>
</tr>
<tr>
<td>implementation</td>
<td>98–109</td>
</tr>
<tr>
<td>implications and challenges</td>
<td>100–109</td>
</tr>
<tr>
<td>supply chain stakeholder requirements</td>
<td>99</td>
</tr>
<tr>
<td>third countries</td>
<td>101</td>
</tr>
<tr>
<td>timeline for implementation</td>
<td>100–109</td>
</tr>
<tr>
<td>FDA-accredited issuing agency (IA)</td>
<td>96</td>
</tr>
<tr>
<td>Federal Commission for the Protection against Sanitary Risk (DOFEPRIS), pharmaceutical product regulation</td>
<td>202</td>
</tr>
<tr>
<td>Federal Trade Commission (FTC), false claim regulation</td>
<td>74</td>
</tr>
<tr>
<td>Field Safety Corrective Action (FSCA), reasons for</td>
<td>385</td>
</tr>
<tr>
<td>field safety notices (FSNs), content and actions required</td>
<td>385–388</td>
</tr>
<tr>
<td>Food and Drug Administration (Taiwan),</td>
<td></td>
</tr>
<tr>
<td>pharmaceutical product regulation</td>
<td>198</td>
</tr>
<tr>
<td>food for special medical purposes (EU)</td>
<td></td>
</tr>
<tr>
<td>categories and composition</td>
<td>568</td>
</tr>
<tr>
<td>classification</td>
<td>569</td>
</tr>
<tr>
<td>EFSA interpretation guidance</td>
<td>569</td>
</tr>
<tr>
<td>food information requirements</td>
<td>570</td>
</tr>
<tr>
<td>placing on market</td>
<td>570</td>
</tr>
<tr>
<td>food for special medical purposes (FSMP)</td>
<td></td>
</tr>
<tr>
<td>562, 565–573</td>
<td></td>
</tr>
<tr>
<td>cost-effectiveness and reimbursement</td>
<td>566–573</td>
</tr>
<tr>
<td>EU framework</td>
<td>568</td>
</tr>
<tr>
<td>intended use</td>
<td>566</td>
</tr>
<tr>
<td>food for special medical purposes (US)</td>
<td></td>
</tr>
<tr>
<td>framework for</td>
<td>567</td>
</tr>
<tr>
<td>medical food definition</td>
<td>567</td>
</tr>
<tr>
<td>foods, dietary supplements, and cosmetics, regulatory</td>
<td></td>
</tr>
<tr>
<td>history and requirements</td>
<td>3</td>
</tr>
<tr>
<td>food supplements</td>
<td></td>
</tr>
<tr>
<td>561, 561–565, 563</td>
<td></td>
</tr>
<tr>
<td>marketing legislation and guidance</td>
<td>562</td>
</tr>
<tr>
<td>quality requirements</td>
<td>563</td>
</tr>
<tr>
<td>reference and intake safety</td>
<td>563–565</td>
</tr>
<tr>
<td>vitamin and mineral supplements</td>
<td>563</td>
</tr>
<tr>
<td>food supplements (EU)</td>
<td></td>
</tr>
<tr>
<td>definition</td>
<td>564</td>
</tr>
<tr>
<td>labeling and health claims</td>
<td>565</td>
</tr>
<tr>
<td>Member State requirements</td>
<td>565</td>
</tr>
<tr>
<td>food supplements (US)</td>
<td></td>
</tr>
<tr>
<td>claims assessment/approval</td>
<td>564</td>
</tr>
<tr>
<td>dietary supplement labeling</td>
<td>564</td>
</tr>
<tr>
<td>dietary supplements</td>
<td>563</td>
</tr>
<tr>
<td>notification for new ingredient/claim</td>
<td>564</td>
</tr>
<tr>
<td>foreign clinical data acceptability, ICH guidances</td>
<td>24</td>
</tr>
<tr>
<td>Form FDA 482</td>
<td>224</td>
</tr>
<tr>
<td><strong>G</strong></td>
<td></td>
</tr>
<tr>
<td>France</td>
<td></td>
</tr>
<tr>
<td>healthcare delivery and funding</td>
<td>131</td>
</tr>
<tr>
<td>HTA comparison with EU countries</td>
<td>153</td>
</tr>
<tr>
<td>freedom of speech</td>
<td>56</td>
</tr>
<tr>
<td>free drug samples in advertising</td>
<td>61</td>
</tr>
<tr>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>healthcare delivery and funding</td>
<td>133</td>
</tr>
<tr>
<td>HTA comparison with EU and UK</td>
<td>153</td>
</tr>
<tr>
<td>process map for</td>
<td>151</td>
</tr>
<tr>
<td>global atlas of medical devices</td>
<td>3</td>
</tr>
<tr>
<td>Global Harmonization Task Force (GHTF)</td>
<td></td>
</tr>
<tr>
<td>device classification principles</td>
<td>335</td>
</tr>
<tr>
<td>history</td>
<td>4</td>
</tr>
<tr>
<td>in-country laws, regulations and guidelines</td>
<td>35</td>
</tr>
<tr>
<td>QMS guidance</td>
<td>330</td>
</tr>
<tr>
<td>submission structure</td>
<td>360</td>
</tr>
<tr>
<td>Global Influenza Surveillance and Response System (GISRS)</td>
<td>467</td>
</tr>
<tr>
<td>global pediatric drug development</td>
<td>597</td>
</tr>
<tr>
<td>Global UDI Database (GUDID)</td>
<td>96</td>
</tr>
<tr>
<td>good clinical practice (GCP)</td>
<td>19</td>
</tr>
<tr>
<td>compliance and</td>
<td>68–81</td>
</tr>
<tr>
<td>ICH guidelines for</td>
<td>19</td>
</tr>
<tr>
<td>veterinary medicinal products</td>
<td>651</td>
</tr>
<tr>
<td>good distribution practice (GDP)</td>
<td></td>
</tr>
<tr>
<td>certificates for</td>
<td>72</td>
</tr>
<tr>
<td>requirements for</td>
<td>70–81</td>
</tr>
<tr>
<td>good documentation practices (GDocP)</td>
<td>72–81, 228</td>
</tr>
<tr>
<td>good laboratory practices (GLP)</td>
<td></td>
</tr>
<tr>
<td>scope of nonclinical studies</td>
<td>67–81</td>
</tr>
<tr>
<td>veterinary medicinal product studies</td>
<td>651</td>
</tr>
<tr>
<td>good manufacturing practice (GMP)</td>
<td>530</td>
</tr>
<tr>
<td>combination products (US)</td>
<td>530</td>
</tr>
<tr>
<td>definition and scope</td>
<td>69–81</td>
</tr>
<tr>
<td>MRCT requirements</td>
<td>22</td>
</tr>
<tr>
<td>US-EU Mutual Reliance Initiative</td>
<td>120</td>
</tr>
<tr>
<td>veterinary medicinal products</td>
<td>648</td>
</tr>
</tbody>
</table>
WHO guidelines 459
good pharmacovigilance practices (GPvP) 72, 72–81
good practice regulations (GXPs) lifecycle management 222
good regulatory practices, for cooperation and reliance 116–121
good vigilance practice. See good pharmacovigilance practices (GPvP)
GS1 Global Location Number (GLN) 107
GS1 Healthcare Reference Guide 107
Gulf Cooperation Council for Drug Registration (GCC-DR) 238
biotechnology product regulation 408
pharmaceutical product regulation 192
Gulf Cooperation Council (GCC)
cosmetic product regulation 636
registration harmonization for pharmaceuticals 238
Gulf States/Region
HTA implementation 157
stability testing and Climatic Zone 218–219

H
harmonization
ASEAN PPWG 5
authorization procedures for prescription pharmaceutical products 187
biotechnology/pharmaceutical product guidelines 393–409
device conformity assessment procedures 296
EU HTA 152–156
Eurasian Economic Union (EAEU/EEU) 5
food safety and quality 563
history of 3
ICH Q7 for GMP 69
IEC 62304 in US and EU 374
IMDRF regional initiatives 4
international regulatory affairs 1
of inspection process 77
regulatory and payer approval 123
unique device identification system 339–354
veterinary medicinal products 644
WHO initiatives 7
Health Authority–Abu Dhabi 193
Health Canada (HC)
ACCESS Consortium 117
pharmacovigilance practices 72
Project ORBIS 119
vaccine regulation 463
healthcare product industry
crisis management 11
types of crises in 11
healthcare products 66
counterfeit and regulations 87
development process for 66
healthcare professionals (HCPs)
advertising to 73
over-the-counter advertising to 61
health claim assessment/approval 564
health effects evaluations 130
Health Policy Forum (HPF) in MENA 157
Health Problem and Current use of Technology (CUR) 147
Health Regulatory Agency (ANVISA), responsibilities 39
Health Sciences Authority (HSA)
ACCESS Consortium 117
human blood and plasma product regulation 502
human blood and plasma products 502
in-country representation 51
pharmaceutical product regulation 195
Health Technology Assessment (HTA) 143
comparison of EU countries and UK 153
definition 143
development in EU 146
domains within 147
economic analysis used in 145
health product market access 144
history 144–145
models used in EU 147
organization and structure of HTA Bodies 147–156
pricing and reimbursement 128
role in decision-making in EU 150–156
UK 150
UK and EU comparison 156
use in decision making 145
herbal medicinal products, applications for 186
Highly Specialised Technologies (HST) evaluations 139
Hong Kong
human blood and plasma products 499
stability testing and climatic zones 215–219
horizontal reliance activities 116
HTA bodies (HTABs) 144
HTA Core Model 147
human blood and plasma products 477
blood product labeling 482
blood product manufacturing process 484
blood product processing controls 489
clinical significance of blood products 478–503
convalescent plasma collection workflow 483
convalescent plasma dosing (Coronavirus epidemic) 485
haemovigilance 484
infection transmission by human blood 487
look-back and trace-back procedures 486
manufactured from blood 479
manufacturing process overview 480
potential risks for manufacturing 488
Index

ICH GCP guideline (E6(R2))
definitions/terms 27
esential documentation for clinical trials 21
GCP principles 23
objective and principles of 23
sponsor requirements 30–34, 31–34
IEC 62366, human factors standard 538
import alerts/distribution bans 78
in–country representation 35, 37
Australia 37
Brazil 39–40
Canada 40
European Union 40–41
typical examples of 37
functions and purposes 36–37
Japan 50
qualifications for 37
Independent Data-Monitoring Committee (IDMC), E6(R2) definition 28
India
approved biosimilar products (India) 443
biosimilar dossier requirements 441
biosimilar product regulation 439
device classification and UDI use 105
generic drug product regulation 257
GMP procedures for pharmaceutical facilities 232
orphan product regulation 518
OTC products 267–271
pharmaceutical product regulation 196–202
stability testing and climactic zones 216–219
track-and-trace and barcode for medicines 104–111
traditional medicine and regulatory framework 576
indirect medical purpose 340
Individual Case Safety Reports (ICSR), for adverse
drug reaction 284–285
induced pluripotent stem cells (iPSCs) 543
infection and microbial contamination risk for devices 291
influenza vaccines, regulatory pathway 466–468
informed consent document (ICD) in MRCTs 22
informed consent, E6(R2) definition 28
infringement on intellectual property 88
INMETRO certification (devices) 74
inspections
by FDA 76
classification of findings 224
corrective actions 224
E6(R2) definition 28
EU process 225
FDA/EMA mutual recognition agreement 120
FDA inspection process 223–224
framework and purpose 222

quality, safety and efficacy 486
regional differences in regulations 489
risk mitigation 480
risks with use of products 480
storage 483
human blood and plasma products (Argentina) 501
human blood and plasma products (Australia)
TG Act 499
TGA regulation 498
Therapeutic Goods Order standards 499
Tissues 499
human blood and plasma products (Canada)
Biologics and Genetic Therapies Directorate regulation 497
Centre for Blood and Tissues Evaluation (CBTE) 497
Certified Product Information Document—Chemical Entities (CPID-CE) 497
current GMP (biological drugs) 498
human plasma collected by plasmapheresis/guidance 498
lot release 497
human blood and plasma products (EU)
GMP, production and quality guidance 491–503
legal framework 489
Official Control Authority Batch Release 492–503
plasma master file (PMF) 492
human blood and plasma products (Hong Kong)
Department of Health regulation 499
Pharmacy and Poisons Ordinance 499
human blood and plasma products (India)
Haemovigilance Programme 500
regulatory agencies and legal framework 500
human blood and plasma products (Japan)
Pharmaceutical and Food Safety Bureau regulation 496
pharmaceutical laws 496
Pharmaceuticals and Medical Devices Act 496
human blood and plasma products (Russia)
dossier requirements 501
licensing system 501
human blood and plasma products (Singapore) 502
human blood and plasma products (US)
blood products approved 481
blood supply regulation 494
CBER regulation 493–503
establishment registration and product listing 494
guidance for risk reduction and prevention 495
legal framework 493
lot release 494
human challenge trials (vaccine development) 459
human factors
combination products 538
IEC 62366 standard 538
harmonization of 77
IVD PMS 337
negative findings from 15
pharmaceutical quality system elements 276
postapproval (follow-up) 229
postapproval inspections 75
preapproval, by regulatory authority 75
Processes 230–241
US biotechnology products 400
inspectorate process, pharmaceuticals 221
Inspectorates Association 77
installation qualification (IQ), GHTF guidance 330
Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
ICH E6(R2) requirements 21
Institutional Review Board (IRB)/Independent Ethics Committee (IEC), E6(R2) definition 28
institution (medical), E6(R2) definition 28
instructions from manufacturer for device 292
integral drug-device combination (iDDC) products 537
intellectual property (IP) infringement, during design phase 91
intended use
foods for special medical purposes 566
“indirect medical purpose” 340
in software regulation 368
laboratory developed tests 349
“lifestyle tests” 340
interchangeability
biosimilar product requirements 434
International Coalition of Medicines Regulatory Authorities (ICMRA)
pharmaceutical product quality 238
pharmaceutical product regulatory harmonization 189
vaccine safety 470
International Coalition of Medicines Regulatory Authorities (ICMRA) membership 6
International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) 4
International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Products (VICH) 644
International Council for Harmonisation (ICH)
clinical trial guidance 20
clinical trials guidance 24
GCP—E6 23
GCP introduction 22
guidelines 19
harmonization of materials for MAA 178–186
harmonization of pediatric drug development 600
ICH Q7 guideline 69
industry guidelines 179
membership 188
pharmaceutical product development/regulatory harmonization 188
pharmaceutical product guidelines 236
pharmacovigilance definition 2
TPLC lifecycle 66
International Electrotechnical Commission (IEC) 62304, software lifecycle process 374
International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Code 57, 59
International Generic Drug Regulators Programme (IGDRP), consolidation with IPRF 6
International Medical Device Regulators Forum (IMDRF)
harmonization 4
MDSAP pilot 4
National Competent Authority Report (NCAR) Exchange Program 3
recommended UDI framework 104
Regulated Product Submission program 337
software/device definitions 368
software guidance 368
Table of Contents (ToC) format 75, 312
International Network of Agencies for Health Technology Assessment (INAHTA) 144
international nonproprietary names (INN)
biosimilars 417
veterinary medicinal products 643
International Organization for Standardization (ISO)
guidance for software 368
ISO 10993 357–358
ISO 13485 66, 323, 327–331, 330, 384
ISO 14971 360, 384
International Pharmaceutical Regulators Forum (IPRF) consolidation of 6
implementation of harmonization 5
International Pharmaceutical Regulators Programme (IPRP) 60
history and benefits of 6
pharmaceutical product regulatory harmonization 189
International Society for Technology Assessment in Health Care (ISTAHC) 144
investigational device exemption (IDE)
de novo classification 347–354
software or firmware 348
Investigational Medicinal Product Dossier (IMPD) 462
investigational medicinal products
E6(R2) definition 28
GMO application for 469
investigator, E6(R2) definition 28
in vitro diagnostic devices (IVDs) 333
ARTG requirements 38
Class A device 338
Class B device 339
Class C device 340
classification principles 334
classification rules 336, 337
conformity assessment elements 335
conformity assessment stages 351
Declaration of Conformity 338
definition 334, 343
device risk class and requirements 335
GHTF classification system 335
PMS and vigilance requirements 342
quality management system 336
regulatory changes for 341–354
technical documentation 337–354
US regulation 342–354
ISO 10993 standard, protection from biological risk 357–358
ISO 13485
2016 requirements 325
CE marking/certificates of compliance for 330
historical perspective 323
in regulatory systems 327–331
postmarket surveillance for devices 384
quality management systems for devices 69
ISO 14971
AIMD risk management 360
postmarket surveillance procedures 384
ISO/IEC 17025 certification 68
Israel, cosmetic product regulation 637
Italy
healthcare delivery and funding 136
HTA comparison with EU countries 153
J
Japan
biosimilar dossier requirements 440
biotechnology product regulation 401
cosmetic product regulation 636
CTD format for MAA 178
drug/device pricing framework 163
GCP standards use 19
generic drug products market 254–260
GMP inspections 232
HTA emphasis in 162
HTA pilot evaluation of products 160
ICH Q7 adoption 69
in-country laws, regulations, and guidelines 36
in-country representation 50
orphan drug designation 519
orphan market exclusivity 512
OTC products in 268
pharmaceutical product regulation 196–202
postmarketing pharmaceutical product requirements 280
vaccine regulation 463
VICH program 4
Joint Inspection Programs 231–241
Jordan, HTA implementation in 157
K
Kenya, HTA implementation 158
Korea. See South Korea
Korea Fair Trade Commission 74
Korea License Holders (KLH), in-country representation 51
Korean Food and Drug Administration (KFDA) 197
L
labeling requirements
AIMDs 360
blood and plasma products (Russia) 501
blood product 482
EU FMD requirements 103
FDA pediatric age categories 602
food information (EU) 570
food supplements 564, 565
OTC products 263–271
revisions for pharmaceutical product 277
under US UDI rule 96
laboratory developed tests (LDTs)
intended use 349
risk-based classification 349
Latin America (LATAM)
biosimilar product regulation 450, 451
biotechnology product regulation 406–409
cosmetic product regulation 634
country-specific HTA overview 167
generic drug market 248–260
HTA development 167–176
HTA timeline in 170
orphan products 517
pharmaceutical product regulation 201–202
stability testing requirements 217–219
laws, regulations, and guidance covered
active implantable medical devices (AIMDs) 355
advertising and promotion 55
authorization procedures for pharmaceutical products 187
biosimilar products 411
botanical drug products 575
cell-based medicinal products 541
clinical trials and GCP 19
combination products 523
cosmetic products 629
food supplements/food for special medical purposes 561
generic drug products 243
global pediatric drug development 597
Health Technology Assessment (HTA) 143
human blood and plasma products 477
in-country representation 35
international counterfeit and regulation 87
international harmonization 1
in vitro diagnostic devices 333
medical device premarket requirements 289
medical device quality management systems 321
orphan product development 507
over-the-counter products 261
pharmaceutical postmarketing and compliance 273–275
postmarket requirements for devices 379
premarket/dossier requirements 177
products derived from biotechnology 391
QMS and inspectorate process 221
reimbursement and pricing 123
software 367
stability test requirements 207
technical and regulatory requirements (devices) 311
vaccines 457–458
veterinary medicinal products 639
Lebanon, pharmaceutical product regulation 192–202
Lenvima (lenvatinib)/Keytruda (pembrolizumab) combination therapy 119
liability of in-country representative
Australian sponsor 39
medicinal products in EU 46–47
lifecycle management (LCM)
combination products (EU) 537–539
device postmarket surveillance system 380
device technical file 386
for IVDs 342–354
software 374
“lifestyle tests” 340
lot release
biotechnology products (Canada) 403
human blood and plasma products 494
Lot Release Program (Canada) 497
US lot/batch release 465
vaccines (Canada) 463
WHO guidance for vaccines 459, 464

HTA adoption in 160–176
pharmaceutical product regulation 194–202
Malaysian Health Technology Assessment Section (MaHTAS) 160
1995–2018 impact 158
historical milestones 159
manufacturing and environmental properties for devices 291
manufacturing and importation authorizations (MIAs), GMP certificates 229
manufacturing/manufacturer
AIMD process validation 361
ATMPs 548
combination products (US) 530–539
device design and requirements 291–309
drug/biological requirements 462
EU authorised representative contract with 44
IVD device registration 338
IVD lifecycle management 342
periodic reports from 386
plasma-derived medicinal products 486
quality control requirements in 68
reporting requirements for devices 387
requirements for compliance 66
US biotechnology products 400
market exclusivity, orphan products 512
marketing authorization application (MAA)
applicability of GxPs 75
bibliographic references and applications 185
certificate of compliance 75
commercialization 178
complete/full and independent applications 184–186
generic or abridged applications 185–186
HTA in 145
maintenance and compliance 276–277
mixed data applications 185
orphan drug 515
platform iDDCs 537
postapproval changes and variations 276
renewal and regional requirements for pharmaceutical products 277
veterinary medicinal products 643
marketing authorization holder (MAH)
biotechnology product documentation 397
compliance by 76
compliance requirements 66
VAMF certification (EU) 469
market withdrawal 78
master files, for clinical trial 21
mechanical risk protection for devices 292
medical device conformity assessment elements, quality management system 321–331
medical device data systems (MDDS) 368
Medical Device Incident Report (MDIR) System 39

M
major deficiency (inspection) 224
Malaysia
medical device quality management system (MDQMS) 321
conformity assessment requirements 323
design and development control steps 325
design controls on the design process 326
interrelated processes 322
ISO 13485 historical perspective 323–331
ISO 13485 in regulatory systems 327–331
medical device conformity assessment elements 321
PDCA methodology 323
process validation 330–331
QMS vs GMP 322–331
medical devices. See also software
active implantable medical devices 355
ARTG listing for 38
combination products 523
essential principles of safety and performance 290
EU regulation changes 40–41
EU risk classification 297
GHTF risk classification 296
in vitro diagnostic devices 333
postmarket requirements 379
premarket requirements 289
quality management systems 321
registration in EU 45
regulatory history 2
regulatory requirements 311
safety and efficacy studies for 68
technical and regulatory requirements 311
US device classification 297
Medical Device Single Audit Program (MDSAP) Pilot 4
Medical Dictionary for Regulatory Activities (MedDRA)
adverse event/drug reaction reporting 285
coding hierarchy 282
standardized terminology 188
medical food. See food for special medical purposes (FSMP)
medicinal products
ADR reporting for marketed 27
botanical drug products 575
cell-based 541
food for special medical purposes/supplements 561
medicines 38
postmarketing safety surveillance 281–285
traditional medicine 575
veterinary 639
Medicines and Healthcare products Regulatory Agency (MHRA)
ACCESS Consortium 117
advertising and promotion regulation 58
refusal to grant inspection 78
Medicines and Medical Devices Safety Authority (Medsafe) 199
Member States (EU)
CEP recognition 182
medicinal product pricing 125
PIC/S membership 235
postapproval inspection responsibility 75
pricing and reimbursement 123
vaccine lot testing and release 464
meningitis B vaccine pricing 123
Messenger ribonucleic acid (mRNA) vaccines 469
Mexico
biosimilar product regulation 452
dossier format 179
generic drug products market 251–260
pharmaceutical product regulation 202
PIC/S membership 232
stability testing and climatic zone 218
Middle East. See also Africa and Middle East (AME) region
biosimilar product regulation 453
biotechnology product regulation 408
cosmetic product regulation 636
Middle East and North Africa (MENA) countries. See also Africa and Middle East (AME) region
health policy network in 157
HTA implementation 156
pharmaceutical product regulation 192–202
Ministry of Food and Drug Safety (MFDS) 518
approved biosimilar products 447
biosimilar guidelines 445
in-country representation 51
orphan disease criteria 518
pharmaceutical product regulation 197
Ministry of Healthcare (Minzdrav), pharmaceutical regulation 201
Ministry of Health, Labour and Welfare (MHLW)
biosimilar guidelines 434
ICH Q7 adoption 69
Ministry of Public Health (MOPH) 192
Module 1 CTD, region-specific administrative information 180
Module 2 CTD, summaries 180
Module 3 CTD 181–184
Module 4 CTD 183–184
Module 5 CTD 183–184
monitoring/monitoring committee, E6(R2) clinical trial progress assessment 28
Monographs of the European Pharmacopoeia 182
Morocco, inspection process 232
Multiple Technology Appraisal (MTA) 139
Multi-Regional Clinical Trials (MRCT) challenges of 20
clinical factors in 21
operational 22
Index

planning issues in 20
mutual confidentiality agreements 119
Mutual Recognition Agreements (MRAs)
definition 114
EU status 230, 230–241
GCP standards for 19

N
National Academies of Sciences, Engineering, and Medicine (NASEM) 563
National Administration for Medicines, Food and Medical Devices (ANMST) 201
National Administration of Drugs, Foods, and Medical Devices (ANMAT) 501
National Agency for Food and Drug Administration and Control (NAFDAC) 192
National Agency of Pharmaceutical Products (ANPP) 189
National Center for Complementary and Integrative Health (NCCIH) 581
national competent authorities
functions and inspections 225
WHO vaccine prequalification 460
National Competent Authority Report (NCAR)
exchange criteria and report format 381–388
Exchange Program 3
National Control Laboratory (NCLs), vaccine lot release 459
National Coordinating Centre for Health Technology Assessment (NCCHTA) 138
National Evidence-based healthcare Collaborating Agency (NECA)< 162
National Formulary (NF) 234
National Health Insurance (NHI) system (South Korea) 161
National Health Service (NHS) 137
National Health Service (NHS), NICE as advisory body to 154
National Institute for Health and Care Excellence (NICE) 138, 154
National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) 108
National Insurance (NI) 137
National Medical Products Administration (NMPA)
clinical trial guidance 20
ICH Q7 adoption 69
pharmaceutical product regulation 195
postapproval change classification 279
UDI device identification rules 108
National medicines regulatory authorities (NRAs) 113
National Pharmaceutical Regulatory Agency (NPRA) 194
New Active Substance Working Group (NASWG) 118–121
new drug application (NDA), for botanical drug products 585
New Zealand
biosimilar product regulation 445, 450
pharmaceutical products regulation 199–202
prescription drug advertising 73
Nigeria, pharmaceutical product regulation 192–202
nonclinical studies
pharmaceutical/medicinal products 68
US biotechnology products 399
vaccine development guidance 459
noncommunicable diseases (NCDs), generic drug market 257
nonprescription drugs. See over-the-counter (OTC) products
North Africa
biotechnology product regulation 408
cosmetic product regulation 637
North America
generic drug regulation 246–247
HTA development in 165–176
Northern Ireland, HTA use in 154
notified body opinion (NBOp) 536

O
Oceania. See Australia; See New Zealand
Office of Blood Research and Review (OBRR)
divisions 494
Official Control Authority Batch Release (OCABR) 465
decision flowchart for biological products 465
human blood and plasma products 492
Official Medicinal Control Laboratories (OMCLs), vaccine lot release 461
off-label use, crisis management 15
off-the-shelf (OTS) software, guidance on use 371
oncology products, EMA authorization and HTA decision 152
operational qualification (OQ), GHTF guidance 330
foreign reviews (UFR) initiative 618
Organisational Aspects (ORG) 147
Organisation for Economic Co-operation and Development (OECD)
evidence-based international standards 7
GLP guidelines 238
promoting cooperative efforts 117
Organisation of Islamic Cooperation (OIC), membership 7
organizational crises 14–17
orphan products 507
accelerated/priority review 511
clinical trials 515–520
Index

development 508–520

drug application and designation status 513
epidemiological prevalence 509–520
FDA expedited programs 512
fee reductions 511
financial benefits 519–520
framework for orphan drugs 513
incentives and legislation 510–520
market exclusivity 512
preclinical/nonclinical requirements 515
Pre-Licensing Access 511
pricing and reimbursement (EU/US) 514
rare disease development programs 509
rare diseases and orphan indications 508–520
regional specificities 516
regulatory 519
regulatory procedure 513–520
outsourcing of software 376
over-the-counter (OTC) products 261
acronyms list 261
advertising of 60, 73
advertising to healthcare professionals 61
BDP market access 585
country-specific information 264–271
definition 261–271
indications for use 262–271
other countries 267–268
prescription switch to 262–271
safety requirements 262–271
switching procedures 265–271

P

Pan American Health Organization (PAHO) biotechnology products 405–409
GMP for pharmaceutical products 238
harmonization of vaccine regulation 460
IMDRF status 4
Pan-American Network on Drug Regulatory Harmonization (PANDRH) biotechnology product harmonization 405
regulatory authority membership 6
Vaccines Working Group 460
Patient-Centered Outcomes Research Initiative (PCORI) 166
patient information leaflet (PIL) 394
Patients and Social Aspects (SOC) 147
pediatric drug/research development global research networks 601
global strategy 600
ICH guidance 600
integration into development process 599
market exclusivity 602, 618
national/regional initiatives 601

Pediatric Cluster 600–627
phases of PIPs 612
pediatric drug/research development (Australia) considerations for sponsors/applicants 619
regulatory approach of TGA 619
pediatric drug/research development (Canada) pediatric exclusivity 618
sponsors/applicants considerations 618
use of foreign reviews (UFR) initiative 618
pediatric drug/research development (EU) Paediatric Investigation Plan (PIP) 612
Paediatric Regulation 611
Paediatric Regulation requirements/incentives 610
sponsor/applicant special considerations 613
timeline of initiatives 609
waivers and deferrals 613
pediatric drug/research development (Japan) considerations for sponsors/applicants 620
new drug re-examination period extension 620
premium reimbursement rate 620
pediatric drug/research development (Switzerland) initiatives 616
PIP with foreign approval 616
pediatric drug/research development (UK) assessment pathways for UK-PIP 615
modified UK-PIP assessment pathways 617
UK-PIP and EU-PIP 614
pediatric drug/research development (US) age categories for pediatric drugs 602
Best Pharmaceuticals for Children Act (BPCA) 602
BPCA and PREA overview 605
Initial Pediatric Study Plan (iPSP) 604
iPSP Process overview 607
outline of the initial Pediatric Study Plan 608
Pediatric Research Equity Act (PREA) 602
rare pediatric disease priority review voucher program 608
sponsor/applicant requirements 611
timeline for actions in US 603
waivers and deferrals 608
performance and clinical evaluation 293
Periodic Adverse Drug Experience Report (PADER) requirements 281
Periodic Benefit–Risk Evaluation Report (PBRER), for NDA and ANDA 281
periodic cumulative reports of safety, PADER and PBRER 285
periodic safety update reports (PSURs) CCDS specifications 277
centralised procedure requirements 394
veterinary medicinal products 652
Peru, biosimilar product regulation 453
pharmaceutical quality system elements 275
Pharmaceutical and Food Safety Bureau (PFSB) 496
Pharmaceutical Inspection Convention (PIC), GMP for pharmaceutical products 189
Pharmaceutical Inspection Co-operation Scheme (PIC/S)
history 4
pharmaceutical product regulatory harmonization 188
Pharmaceutical Inspection Cooperation Scheme (PIC/S)
compliance requirements 69–81
FDA membership 224
GMP inspections 77
pharmaceutical inspections 237
regulatory reliance in 113
pharmaceutical postmarketing and compliance
authorization maintenance and regulatory compliance 276–277
drug safety reporting and compliance 281–285
MAH reporting requirements 283
postapproval requirements 277
product updates by MAH 274–275
quality compliance to GMPs 274–275
renewal of the marketing authorization 277
pharmaceutical products 243
authorization procedures 187
generic drug products 243
GMP regulations for drugs 222
human blood and plasma products 477
MRCT value in development 20
pediatric drug development 597
postmarketing compliance 273
QMS and inspectorate process 221
regulatory history of drugs 2
stability testing for 207
WHO guidance 459
pharmaceutical quality system elements
change management system 275
corrective action preventive action system 275
inspections 276
process performance and quality monitoring 275
standard operating procedures 275
Pharmaceuticals and Medical Devices Act (PMD Act) 496
Pharmaceuticals and Medical Devices Agency (PMDA)
approved biosimilars 438
clinical trial guidance 20
HTA in reimbursement prices 163
ICH Q7 adoption 69
pharmaceutical product regulation 196
Pharmacopoeial Compendia 234
pharmacovigilance
Australian sponsor responsibilities 39
elements of 2
ICH guidance (E2a–E2F) 24
in-country representative in EU 48
OTC postmarket reporting 264–271
vaccines 471
veterinary medicinal products 651
WHO definition 2
Pharmacy and Poisons Ordinance 499
plasma master file (PMF) 398
postauthorization safety study (PASS), pharmaceutical quality system elements 277
postmarketing safety surveillance of medicines
adverse event reporting 281–285
drugs for rare disease 516
Individual Case Safety Reports (ICSR) 284–285
medical coding for report 285
postmarket requirements (devices) 379
combination products (US) 531
criteria for competent authority reporting 383
distribution records for traceability 381
FSCA and CAPA plans 384–388
periodic reports 386
postmarket surveillance activities 384–388
vigilance reporting in PSSS 380–388
postmarket requirements (pharmaceutical)
pharmaceutical product compliance 273
safety-event management 13
surveillance studies 653
veterinary medicinal products 651
postmarket surveillance system (PMSS), devices in EU 380
postmarket surveillance/vigilance system (PMS)
Australian in-country representative 39
combination products (EU) 538–539
devices in EU 47–48
for IVDs 337
premarket approval application (PMA)
AIMDs 362
IVDs 347
premarketing authorization (PMA) holders compliance by 76
Premarket Notifications (510(k), IVDs 346
premarket requirements 177
ACTD format and content 184
medical devices 289
medicinal products evaluation 177–186
premarket requirements/dossier requirement
bibliographic references and applications 185
complete/full and independent applications 184
country-specific regulatory requirements 190
country-specific requirements 186
CTD organization 180
CTD use 178–186
drug products 182–184
generic or abridged applications 185–186
Index

legal framework 182–184
mixed data applications 185–186
pricing and reimbursement
competent authorities 139
cost-based (CbP) model 127
current trends 130
economic evaluations of treatments 129
EU pricing and rembursements 126–142
European Union 123
FSMPs 566
health effects measurement 130
HTA-models case studies 131–142
orphan drugs (EU/US) 514
reference-based pricing model 126
vaccines 472
value-based pricing model 127
primary mode of action (PMOA) 525
primary subject matter expert (SME) 79
Principal Investigator (PI), E6(R2) definition 28
process validation
biological safety 317
components of 330
decision tree for 330
steps involved 330
process validation (device QMS)
facility and equipment validation 330–331
process validation decision tree 328
supplier control 329
Validation Master Plan (VMP) 330
product crises 12
production Identifier (PI) 96
product manufacturers (510(k), compliance 76
Project ORBIS 119–121
promotion 55. See advertising and promotion
Proprietary Association of Great Britain (PAGB),
advocating and promotion regulation 58
protection against radiation from devices 292
protocol
amendment to E6(R2) 29
E6(R2) definition 28

Q

Quality-Adjusted Life Year (QALY) 130, 155
quality assurance, E6(R2) scope of 29
quality control documents (QCDs), E6(R2) addendum
sponsor requirements 32
quality control, scope of E6(R2) 29
Quality Management System for devices (MDQMS),
conformity assessment element 321
quality management system (QMS)
demonstration of supplier control 331
device premarket requirements 293–302
E6(R2) definition 29

E6(R2) sponsor requirements 30
framework for pharmaceuticals 222
inspections of 75
medical devices 321
pharmaceuticals 221
product/services from suppliers 331
supranational, nongovernmental pharmaceutical
product 234
quality management systems/inspectorate process
Associations 238
PIC/s member states 235
remote inspections 239–241
Quality Working Group (M4Q) 179

R

randomization, E6(R2) definition 29
rare disease products. See orphan products
rare diseases-orphan products 508
recalls 78
reference-based pricing model 126
Regulated Product Submission (RPS)
device harmonization initiative 312
format for IVD/non-IVD 317
IMDRF program 337
regulations 19
dispute resolution process 14
globalization effects on 7
regulators' role, statements of responsibility 2
regulatory affairs
advertising and promotion 55–56
history of 2
international 1
MCRT issues 22
regulatory authorities
E6(R2) definition 29
ICH full regulatory members 22
regional 26
regulatory convergence, definition 114
regulatory environment for pharmaceuticals 223
regulatory harmonization, definition 114
Regulatory Harmonization Steering Committee (RHSC) 5
regulatory inspections. See inspections
regulatory professional, role of
communication with regulators 79
inspection support 79–81
professional ethics 80
system owner and SME 79–81
regulatory recognition, definition 114
regulatory reliance
ACCESS Consortium 117
barriers to 116
Caribbean Regulatory System (CRS) 119
Index

definition 114
Generic Medicines Work Sharing Initiative 118–121
good regulatory practices 116–120
horizontal reliance activities 116
national medicines regulatory authorities role in 113–121
New Active Substance Work Sharing Initiative 118–121
pathways for 113
principles of 114–120
successful examples 117–120
terminology for 114–120
unidirectional reliance activities 116
regulatory teams, crisis management team 16
reimbursement. See pricing and reimbursement
Release Letter (vaccine) 463
research and development (R&D), crises related to productivity 13
Respect of national/regional legal basis 116
risk assessment/management
analysis for AIMDs 360
biotechnology products 391
vaccines 471
rolling review procedure, use for COVID-19 vaccines 470
Russia/CIS
biotechnology product regulation 408
generic drug requirements 257
human blood and plasma product regulation 500
orphan designation applications 519
pharmaceutical products regulation 201
regulation and inspection of pharmaceuticals 232
S
safety and/or efficacy assessment
crime management for 12
E6(R2) definition 30
reporting and compliance for medicines 281–285
safety guideline (M4S) 181
Safety (SAF) 147
Safety Working Group (M4S) 179
Saudi Arabia
cosmetic product regulation 637
HTA for high-cost drugs 156
pharmaceutical product regulation 193–202
regulations and inspection of pharmaceuticals 233
Saudi Food and Drug Authority (SFDA) 193
Scotland 156
HTA programs/bodies in 154
process map for 155
Scottish Health Technologies Group (SHTG) 154
Scottish Medicines Consortium (SMC) 154
scrapie 396
self-testing devices, intended use 334
self-testing or self administration device risks 292
serious adverse drug reaction (ADR), E6(R2) definition 27
serious adverse event (SAE), E6(R2) definition 27
similar biotherapeutic products (SBPs). See biosimilar products
Singapore. See Health Sciences Authority (HSA)
biology and plasma product regulation 502
Health Products Regulations Group 502
orphan products 517
pharmaceutical product regulation 195–202
Project ORBIS 119
software 367. See also medical devices as device vs. standalone 368
as regulated medical device 368–378
categories and classification 373–378
decision tree for EU MDR 370
development of 373–378
FDA precertification program 377
in IVDs 348
personal health data protection 376–378
quality management system 376
types and EU qualification 375
software as a medical device (SaMD), definition/characteristics 368
South Africa
biotechnology products regulation 408
cosmetic product regulation 637
HTA implementation 157
pharmaceutical product regulation 192
PIC/S alignment 233
stability testing and climatic zone 218–219
South African Health Products Regulatory Authority (SAHPRA) 192, 453
Southern/Eastern Europe (SEE)
biotechnology products regulation 407
stability testing and climactic zones 218–219
South Korea
barcode or RFID tag for medicines 107–111
biosimilar dossier requirements 448
biosimilar product regulation 445
cosmetic product regulation 636
HTA flow diagram 162
HTA introduction in 161–176
in-country representation 51
National Evidence-based healthcare Collaborating Agency (NECA) 162
orphan designation criteria 518
pharmaceutical product regulation 197–202
regulations and inspection of pharmaceuticals 233
UDI framework for devices 107
sovereignty of decision-making 116
Spain
732
Regulatory Affairs Professionals Society
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Index</td>
<td>733</td>
</tr>
<tr>
<td>healthcare delivery and funding</td>
<td>135–136</td>
</tr>
<tr>
<td>HTA comparison with EU countries</td>
<td>153</td>
</tr>
<tr>
<td>sponsor requirements, ICH E6(R2)</td>
<td>32</td>
</tr>
<tr>
<td>allocation of responsibilities</td>
<td>32</td>
</tr>
<tr>
<td>clinical trial/study reports</td>
<td>32</td>
</tr>
<tr>
<td>compensation to subjects and investigators</td>
<td>32</td>
</tr>
<tr>
<td>contract research organization (CRO)</td>
<td>31</td>
</tr>
<tr>
<td>investigational products</td>
<td>31</td>
</tr>
<tr>
<td>monitoring/monitoring committee</td>
<td>32</td>
</tr>
<tr>
<td>multi-center trials</td>
<td>32</td>
</tr>
<tr>
<td>quality assurance</td>
<td>31</td>
</tr>
<tr>
<td>quality control</td>
<td>31</td>
</tr>
<tr>
<td>risk communication</td>
<td>31</td>
</tr>
<tr>
<td>risk control</td>
<td>30</td>
</tr>
<tr>
<td>risk evaluation</td>
<td>30</td>
</tr>
<tr>
<td>risk identification</td>
<td>30</td>
</tr>
<tr>
<td>risk reporting</td>
<td>31</td>
</tr>
<tr>
<td>risk review</td>
<td>31</td>
</tr>
<tr>
<td>source documents</td>
<td>33</td>
</tr>
<tr>
<td>standard operating procedures (SOPs)</td>
<td>32</td>
</tr>
<tr>
<td>trial master file (TMF)</td>
<td>32</td>
</tr>
<tr>
<td>sponsor/sponsor-investigator</td>
<td>29</td>
</tr>
<tr>
<td>E6(R2) definition</td>
<td>29</td>
</tr>
<tr>
<td>E6(R2) requirements</td>
<td>30</td>
</tr>
<tr>
<td>stability test requirements</td>
<td>207</td>
</tr>
<tr>
<td>analytical procedures for</td>
<td>210–219</td>
</tr>
<tr>
<td>choice and characteristics of test batches</td>
<td>209–219</td>
</tr>
<tr>
<td>climatic zones</td>
<td>208</td>
</tr>
<tr>
<td>commitment for continued testing</td>
<td>213</td>
</tr>
<tr>
<td>container closure system</td>
<td>210</td>
</tr>
<tr>
<td>country-specific climatic zones (SEE, Middle East, Africa)</td>
<td>218</td>
</tr>
<tr>
<td>during product lifecycle</td>
<td>209–219</td>
</tr>
<tr>
<td>evaluation for retest period</td>
<td>213–219</td>
</tr>
<tr>
<td>international guidelines</td>
<td>208</td>
</tr>
<tr>
<td>in-use testing</td>
<td>214–219</td>
</tr>
<tr>
<td>labeling and statements</td>
<td>214–219</td>
</tr>
<tr>
<td>Latin America country-specific climatic zones</td>
<td>217</td>
</tr>
<tr>
<td>refrigerated/frozen storage conditions</td>
<td>213</td>
</tr>
<tr>
<td>Requirements</td>
<td>215–219</td>
</tr>
<tr>
<td>specific intended storage conditions</td>
<td>212</td>
</tr>
<tr>
<td>storage conditions</td>
<td>211–219</td>
</tr>
<tr>
<td>stress testing</td>
<td>209–219</td>
</tr>
<tr>
<td>testing frequency</td>
<td>211–219</td>
</tr>
<tr>
<td>variations in drug product</td>
<td>214</td>
</tr>
<tr>
<td>WHO testing condition recommendations</td>
<td>212</td>
</tr>
<tr>
<td>standalone product (herbal)</td>
<td>583</td>
</tr>
<tr>
<td>standard operating procedures (SOPs)</td>
<td>29</td>
</tr>
<tr>
<td>E6(R2) definition</td>
<td>29</td>
</tr>
<tr>
<td>equipment and process validation</td>
<td>331</td>
</tr>
<tr>
<td>equipment related</td>
<td>331</td>
</tr>
<tr>
<td>pharmaceutical quality systems</td>
<td>275</td>
</tr>
<tr>
<td>process-related</td>
<td>331</td>
</tr>
<tr>
<td>statistical analysis</td>
<td>316</td>
</tr>
<tr>
<td>for MRCTs</td>
<td>20</td>
</tr>
<tr>
<td>ICH E10</td>
<td>25–26</td>
</tr>
<tr>
<td>ICH statistical principles (E9)</td>
<td>24</td>
</tr>
<tr>
<td>sterilization validation</td>
<td>317</td>
</tr>
<tr>
<td>stock recovery</td>
<td>78</td>
</tr>
<tr>
<td>sub investigator, E6(R2) definition</td>
<td>29</td>
</tr>
<tr>
<td>subject/trial subject, E6(R2) definition</td>
<td>29</td>
</tr>
<tr>
<td>Sub-Saharan African countries, HTA implementation</td>
<td>156, 157</td>
</tr>
<tr>
<td>sulfathiazole tablets</td>
<td>69</td>
</tr>
<tr>
<td>summary of product characteristics (SmPC)</td>
<td>394</td>
</tr>
<tr>
<td>Summary Technical Documentation (STED) guidance</td>
<td>294, 312</td>
</tr>
<tr>
<td>supplied energy or substance risks</td>
<td>292</td>
</tr>
<tr>
<td>Sweden, value-based pricing in</td>
<td>131</td>
</tr>
<tr>
<td>Swedish Council on Technology Assessment in Health Care</td>
<td>146</td>
</tr>
<tr>
<td>Switzerland</td>
<td></td>
</tr>
<tr>
<td>Project ORBIS</td>
<td>119</td>
</tr>
<tr>
<td>regulation and inspection process for pharmaceuticals</td>
<td>233</td>
</tr>
<tr>
<td>system owner</td>
<td>79</td>
</tr>
</tbody>
</table>

T

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table of Contents (ToC) format</td>
<td>75, 312</td>
</tr>
<tr>
<td>clinical evidence (Chapter 4)</td>
<td>317–319</td>
</tr>
<tr>
<td>harmonization for IVD submissions</td>
<td>338</td>
</tr>
<tr>
<td>labeling and promotional material (Chapter 5)</td>
<td>317–319</td>
</tr>
<tr>
<td>non-clinical evidence (Chapter 3)</td>
<td>315–319</td>
</tr>
<tr>
<td>regional administrative (Chapter 1)</td>
<td>314–319</td>
</tr>
<tr>
<td>submission context (Chapter 2)</td>
<td>315–319</td>
</tr>
<tr>
<td>Taiwan</td>
<td></td>
</tr>
<tr>
<td>in-country representation</td>
<td>51</td>
</tr>
<tr>
<td>orphan products</td>
<td>518</td>
</tr>
<tr>
<td>pharmaceutical inspections</td>
<td>233</td>
</tr>
<tr>
<td>pharmaceutical product regulation</td>
<td>198–202</td>
</tr>
<tr>
<td>stability testing and climatic zone</td>
<td>217</td>
</tr>
<tr>
<td>Taiwan Food and Drug Administration (TFDA)</td>
<td>51</td>
</tr>
<tr>
<td>technical and regulatory requirements for devices</td>
<td></td>
</tr>
<tr>
<td>corrective and preventive actions</td>
<td>319</td>
</tr>
<tr>
<td>design and development and planning</td>
<td>319</td>
</tr>
<tr>
<td>essential technical file elements</td>
<td>312–319</td>
</tr>
<tr>
<td>GHTF submission guidance by device class</td>
<td>313</td>
</tr>
<tr>
<td>outsourcing</td>
<td>319</td>
</tr>
<tr>
<td>postmarket use of STED</td>
<td>314</td>
</tr>
<tr>
<td>risk management principles</td>
<td>318–319</td>
</tr>
<tr>
<td>RPS documentation/ToC requirements</td>
<td>313–319</td>
</tr>
<tr>
<td>RPS format</td>
<td>317</td>
</tr>
<tr>
<td>use of standards</td>
<td>318–319</td>
</tr>
<tr>
<td>verification and validation</td>
<td>316</td>
</tr>
</tbody>
</table>
Index

technical file/design dossier elements
  postmarket phase 312
  premarket phase 312
  submission before market entry 312
technology appraisal (TA) committees (NICE) 154
  technology assessment in HTA 145
thalidomide 69
The Americas
  harmonization organizations in 6–7
  HTA implementation in North America 165–176
Therapeutic Goods Administration (TGA)
  ACCESS Consortium 117
  cosmetic product regulation 636
  human blood and plasma products 498
  pharmaceutical product regulation 198
  Project ORBIS 119
  provisional registration for COVID-19 vaccines 470
  vaccine regulation 464
therapeutic products. See healthcare products
thiomersal (thimerosal) 466
tissue engineered products (TEPs) 543
ToC Chapter 1
  Declaration of Conformity 315
  topics covered 314–320
ToC Chapter 2
  device description 315–320
  global market history 315
  indications/intended use 315
  similar/previous device generations 315
ToC Chapter 3
  animal studies for device conformity 317
  biological safety 317
  Essential Principles checklist 315
  materials biocompatibility 316
  medicinal substances in devie 317
  product verification and validation 316
  risk management 315
  software verification and validation 316
  sterilization validation 317
ToC Chapter 4, clinical evicence of EP conformity 317
ToC Chapter 5, labeling and promotional material 317
  total product lifecycle (TPLC) approach/methodology 66
  GMP regulations for 222
  vigilance in 72
  traditional Chinese medicine (TCM)
    education and practice reports 580
    fundamentals 578–593
    regulatory framework 579–593
  Traditional Herbal Medicine in EU
    herbal medicinal product definition 583
    new herbal product marketing approval pathways 583
    registration procedure for products 583
    traditional medicine 575, 576
  Africa and South America 584
  product regulations in selected countries 579
  traditional medicine (India) 576
    basis of 576
    education and practice 578
    regulatory framework 577–593
  traditional medicine in the US. See complementary and
    alternative medicine (CAM)
  traditional medicine (US). See also botanical drug
    products (BDPs); See complementary and
    alternative medicine (CAM)
  traditional use product (herbal) 583
  Transmissible Spongiform Encephalopathies Advisory
    Committee (TSEAC) 494
  transmissible spongiform encephalopathy (TSE) 396
  treatment of subjects, E6(R2) definition 29
  trial master file (TMF), essential documents 33
  Tunisia, HTA implementation 156
  Turkey
    PIC/S alignment 233
    serialization of medicines in 107–111
    UDI-like system for devices 108
  21st Century Cures Act 556

U
  “ultra-rare diseases” 509
  unidirectional reliance activities 116
  unique device/drug identification (UDI)
    global harmonization 339
    IMDRF guidance on 104
    in prevention of counterfeit/falsification 90
    unique product identifiers (UPIs)
    ARTG requirements for 38
    United Arab Emirates (UAE)
      pharmaceutical product regulation 193–202
  United Kingdom (UK) 77. See also England
    advertising and promotion regulation 58
    EU-UK Trade and Cooperation Agreement 126
    healthcare delivery and funding 137–142
    HTA comparison with EU countries 153
    HTA programs in 154–156
    in-country representation changes 43–44
    in-country representation laws, regulations, and
      guidelines 36
    Joint Committee on Vaccination and Immunisation
      (JCVI) 124
    pharmaceuticals regulations and inspections 234
    surveillance approach in 77
    value-based pricing 131
  United States (US)
    advertising and promotion regulation 58
    AIMD requirements 362–365
    botanical drug products (BDPs) 584–593
### Index

- **combination products** 526–539
- **cosmetic product regulation** 631
- **CTD format for MAA** 178
- **determining OTC status** 265–271
- **false claim regulation** 73
- **GCP standard use** 19
- **HTA implementation** 165–176
- **“HTA-like bodies”** 165
- **in-country representation** 50
- **in-country representation laws, regulations, and guidelines** 36
- **IVD regulations** 342–354
- **orphan products** 516–520
- **PADER AND PBRER reporting** 281
- **pharmaceutical quality management/inspectorate process** 223
- **prescription drug advertising** 73
- **QSR for quality management** 327–331
- **recalls, classification of** 78
- **software regulation** 371
- **VICH program** 4

**United States (US) medical device reporting**

- **importers** 387
- **legal framework** 387–388
- **user facilities requirements** 387

**unregulated software** 372

**US Drug Supply Chain Security Act (DSCSA)** 91

- **aims and scope of** 91–111
- **dispensers’ implementation of** 94–111
- **implentation for dispensers** 92–111
- **implications and challenges of** 94
- **terminology and stakeholders definitions** 92

**US-EU Mutual Reliance Initiative** 120

**US Food and Drug Administration (FDA)**

- **Blood Products Advisory Committee (BPAC)** 494
- **civilmoney penalties for noncompliance** 78
- **clinical trial guidance** 20
- **commercialization/post commercialization regulation** 76–81
- **devartment** 78
- **eCTD submission requirements** 179
- **ICH Q7 adoption** 69
- **influenza vaccines guidance** 468
- **marketing approval process for BDPs** 584
- **medical device GMPs** 69
- **medical food framework** 567
- **mutual recognition agreement with EMA** 120
- **oversight of IVDs** 342
- **pharmaceutical quality management** 223
- **post inspection observations** 77
- **postmarketing requirement (PMR)** 277
- **Postmarket Surveillance Studies Program** 384
- **Project ORBIS** 119
- **QSR and ISO 13485** 327

**rare pediatric disease designation/priority review** 608

**regulatory reliance for oncology products** 119–121

**software classification revision** 371–372

**software precertification program** 377

**timeline counterfeit and regulation implementation** 93

**waivers and deferrals for pediatric research** 608

**Warning Letters** 78

**US IVD regulation**

- **Class I (general controls)** 344–354
- **Class III (premarket approval)** 344–354
- **Class II (special controls)** 344–354
- **CLIA categorization** 345–354
- **cybersecurity with** 348
- **definitions** 343–354
- **investigational device exemption** 347–354
- **oversight of** 342
- **postmarket surveillance** 349
- **premarket submission types** 346–354
- **presubmission program** 345–354
- **risk-based classification** 344

**US Pharmacopoeia (USP)** 234

**US Unique Device Identifier (UDI) System Rule**

- **aims and scope of** 95–109
- **definition and requirements for** 96–109
- **implementation and implications of** 97
- **requirements and implementation** 96–109

**US Vaccines and Related Biological Products Advisory Committee (VRBPAC)** 467, 468

### V

**Vaccine Adverse Event Reporting System (VAERS)** 472

**vaccine antigen master file (VAMF)** 398, 468

**vaccines** 457. See also biotechnology products

- **additives** 466
- **adjuvants** 466
- **clinical trials requirements** 462
- **EU regulation of** 461
- **ICH guidelines** 461
- **influenza vaccine development** 467
- **Japanese regulation of** 463
- **lot release and regulations** 464
- **mRNA vaccines for COVID-19 and pandemic** 469
- **newer approaches to** 469
- **OCABR testing** 464
- **overview** 458
- **pricing and reimbursement** 472
- **QPPV requirements** 472
- **regional/local requirements** 464
- **regulatory agencies** 461
- **risk management and vigilance** 471
- **standard vs. rolling review** 471
Index

therapeutic vaccine products 470
US regulation of 462
WHO functions and guidelines 459
WHO prequalification 460
Vaccine Working Party (VWP) 461
validation, facility and equipment 330
Validation Master Plan (VMP) 330
value-based pricing model 127
Vanessa’s Law 72
Venezuela, orphan drugs 517
verification and validation
AIMD submissions 360–361
device software 316
device sterilization 317
documentation for devices 316
veterinary medicinal products 639
active substance safety information 649
authorization procedures 651
CTD use 646
definitions 643
differences in animal and human products 642
dossier contents 646–656
dossier requirements 644
efficacy dossier section 650
GLP conformity 651
GMP principles 648
harmonization efforts/objectives 644
human/veterinary dossier differences 645
marketing authorization requirements 643
maximum residue limits (major species) 650
maximum residue limits (minor species) 650
pharmacovigilance system 652
postmarketing issues 651
postmarket surveillance studies 653
product development 642
product residue information 646
PSURs 652
quality section of dossier 645
regulatory history 3
residue information for food-producing species 649
safety section of dossier 646
VICH committees/working groups 645
VICH guidelines 647
advertising and promotion recommendations 73
advertising and promotion regulation 57, 59
certification scheme on pharmaceutical products 113
clinical efficacy studies for SBPs 416
counterfeit products 88
country and regional offices of 6
data and record management 73
drug product stability guidelines 208
evaluation procedures for SBPs 416
generic product definition 244
global atlas of medical devices 3
Global Surveillance and Monitoring System 104
good manufacuting practices draft 69
health technology definition 143
herbal and botanical medicines definition 575
HTA definition 128
IMDRF status 4
influenza vaccine recommendations 468
naming SBPs/biosimilars 417
orphan product criteria 517
pharmaceutical product development regulatory
harmonization 188
pharmaceutical product requirements 234–241
pharmaceutical products regulation 201
pharmacovigilance definition 2
postapproval changes to biosimilars 418
price transparency on vaccines 124–125
recommended stability testing conditions 212
Resolution WHA21.41 59
SmPC or PI Prescribing information 418
SmPC/prescribing information 418
stability test requirements 207
standards for biotherapeutic products 415
vaccine safety guidance 469
World Medical Association (WMA) 23
written and tabulated summaries 181

Y

Yearly Biologic Product Report (YBPR) 463

W

Wales, HTA use in 154
well-established product 583
whistle blowers, crisis management 15
willingness-to-pay threshold 130
work-sharing, definition 114
World Health Organization Public Inspection Reports (WHOPIR) 234
World Health Organization (WHO)